Plain-English translation of NCT07366801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new approach to stem cell transplantation for children and young adults with acute leukemia. Doctors will give you stem cells from a donor along with special immune cells called regulatory T lymphocytes, combined with one of four preventive medications (Cyclosporine A, , Ruxolitinib, or ) to reduce the risk of a serious side effect called graft-versus-host disease, where the new immune cells attack your body.
After a stem cell transplant, the new immune cells can sometimes attack the patient's own body, causing a painful and potentially life-threatening condition. This trial is testing whether adding specially selected immune cells and trying different combinations of preventive medications can reduce this risk while still allowing the transplant to work against the cancer.
You likely qualify if…
You likely don't qualify if…
You will receive the stem cell transplant along with the special immune cells and one of the four preventive medications assigned to your group. You'll stay in the hospital for the initial transplant and recovery period, then return for regular clinic visits to monitor your progress, check for side effects, and have blood tests done. You'll need to stay involved with the study team for at least 3 years after your transplant so they can track how well the treatment is working and whether it reduces the risk of complications.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
Russia